Findings

What do systematic reviews say?

16 questions · 16 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 25%GRADE not reported 0 · 0%Very low 7 · 43.8%Low 3 · 18.8%Moderate 2 · 12.5%High 0 · 0%

DPP‐4 inhibitors vs insulin glargine

Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DPP‐4 inhibitors vs insulin glargine

Delayed graft function · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DPP‐4 inhibitors vs insulin glargine

HbA1c (%) · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

DPP‐4 inhibitors vs insulin glargine

FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

DPP‐4 inhibitors vs insulin glargine

Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DPP‐4 inhibitors vs insulin glargine

Death (any cause) · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DPP‐4 inhibitors vs insulin glargine

Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

DPP‐4 inhibitors vs insulin glargine

Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Very low

DPP‐4 inhibitors vs placebo

FBG (mmol/L) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 589 participants
Low

DPP‐4 inhibitors vs placebo

Death (all causes) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 4211 participants
Low

DPP‐4 inhibitors vs placebo

All cardiovascular death · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 5897 participants
Moderate

DPP‐4 inhibitors vs placebo

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 210 participants
Moderate

DPP‐4 inhibitors vs placebo

eGFR · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 130 participants
Very low

DPP‐4 inhibitors vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 1443 participants
Very low

DPP‐4 inhibitors vs placebo

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1257 participants
Very low

DPP‐4 inhibitors vs placebo

HbA1c (%) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 867 participants
Low